Surgical excision in dromedary camels yields 83.70% recovery with 16.30% complications across cutaneous and subcutaneous masses.
Most Camel Skin Lumps Don’t Turn Cancerous
This cohort study of 92 confirmed cases in Saudi Arabia evaluated surgical excision for cutaneous and subcutaneous masses in dromedary camel…
Most skin lumps in camels aren’t cancerous, and surgery fixes them in over 80% of cases—offering clear guidance for herds in arid regions wh…
Stapokibart plus glucocorticoids achieves disease control in elderly bullous pemphigoid patients
Trial shows stapokibart helps elderly bullous pemphigoid patients
In a single-center, retrospective, uncontrolled case series of 15 elderly patients with moderate-to-severe bullous pemphigoid, all achieved …
A small study found that adding stapokibart to standard therapy helped elderly patients with severe bullous pemphigoid control their skin di…
Genetic burden in PI3K–AKT–mTOR pathway linked to microscopic polyangiitis susceptibility in Chinese cohort
Genetic markers linked to higher risk of microscopic polyangiitis in Chinese patients
This observational cohort study in a Chinese population examined genetic burden across the PI3K–AKT–mTOR pathway and susceptibility to micro…
A specific genetic load tied to a key cell pathway raises the risk of microscopic polyangiitis, offering new clues for prevention and care.
Pilot RCT protocol assesses VR-PAT game versus dark screen for pain and anxiety in pediatric laser therapy.
A new game might help children feel less pain during laser treatments.
This pilot feasibility randomized clinical trial protocol evaluates a Virtual Reality Pain Alleviation Therapeutic (VR-PAT) game against a d…
A new game called VR-PAT could help kids feel less pain and anxiety during laser therapy, but final results are still coming.
Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
Herring roe oil may lower inflammation in psoriasis
In a randomized controlled trial post hoc analysis of 64 patients with mild-to-moderate psoriasis, oral herring roe oil supplementation for …
A small trial found that herring roe oil reduced several blood-based inflammation markers in people with mild-to-moderate psoriasis over 26 …
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
675-nm Diode Laser as Adjuvant Therapy for Telogen Effluvium: A Retrospective Case Series
Laser Therapy Shows Promise for Stubborn Hair Shedding
This retrospective case series of 13 patients with telogen effluvium found that adjuvant 675-nm diode laser therapy was associated with impr…
For people struggling with ongoing hair shedding, a gentle laser treatment may offer a new way to help hair grow back safely.
MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study.
New Blood Test Could Spot Psoriasis Earlier, Study Suggests
This retrospective case-control study evaluated MONO, ORM1, ORM2, and AGP levels in 140 participants, including 70 patients with dermatology…
This research offers a new way to spot psoriasis risk early using a simple blood test, which could lead to faster treatment and better skin …
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
The FDA has approved a new drug called Cosentyx for treating a serious skin condition.
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older. It is a biologic drug that targets inf…
FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
The FDA approved a new use for the drug Cosentyx to treat a painful skin condition.
The FDA has approved Cosentyx for moderate to severe hidradenitis suppurativa in adults and pediatric patients 12 years and older. This inte…
The FDA has approved Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. …
Review suggests automated stool management system may reduce costs and nursing time in ICU fecal incontinence
New Device Cuts ICU Fecal Incontinence Costs By 90%
This narrative review synthesizes evidence on the Qoramatic Automated Stool Management system versus traditional methods for fecal incontine…
A new automated device could save hospitals thousands of dollars while keeping patients cleaner and safer.
Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk.
Atopic Dermatitis Raises Psoriasis Risk, But Biologics Help
This narrative review synthesizes findings from a large cohort study. It reports an association between atopic dermatitis and increased inci…
A massive study shows that while eczema increases the chance of getting psoriasis, modern biologic drugs significantly protect against this …